Impact of Hepatitis C Virus Therapy on Central Nervous System Outcomes
Status:
Recruiting
Trial end date:
0000-00-00
Target enrollment:
Participant gender:
Summary
This partially blinded placebo-controlled trial will determine the impact of curing
Hepatitis C Virus (HCV) with an oral direct-acting antiviral (DAA), ledipasvir and
sofosbuvir in a single pill, on central nervous system (CNS) outcomes in mono- or Human
Immunodeficiency Virus (HIV) co-infected individuals.
Phase:
Phase 4
Details
Lead Sponsor:
University of California, San Diego
Collaborator:
Gilead Sciences
Treatments:
Ledipasvir Ledipasvir, sofosbuvir drug combination Sofosbuvir